Ausgewählte Vorträge

Seit 2015

2017

Neue Präsentationen eigener Arbeitsergebnisse:

ISPOR 20th Annual European Congress
Glasgow / Schottland, 04.-08. November 2017:

  1. Empirical studies on the economic Value of a Statistical Life Year (VSLY) in Europe: what do they tell us?
  2. "Appraising the Appraisers" Do national Health Technology Assessment (HTA) agencies (NICE, GBA/IQWiG) follow their official evaluation criteria?

Weitere Vorträge:

2017 HTAi Annual Meeting
Rom / Italien, 17.-21. Juni 2017:

Michael Schlander, Ramon Schäfer, Oliver Schwarz:

An Update on the Economic Value of a Statistical Life Year in Europe.

Ramon Schäfer, Michael Schlander:

Is NICE in the UK more Innovation-Friendly than IQWiG/GBA in Germany?

MedTechDialog „Kosten-Nutzen-Bewertung / HTA für Medizinprodukte“
Mannheim, 23. März 2017:

Health Technology Assessment (HTA) im deutschen Medizinproduktemarkt: Prinzipien, Prozesse, exemplarische Umsetzung.
(Health Technology Assessment (HTA) for Medical Products – How to Cope with the Increasing Regulatory Burden?)

Der Marktzugang für Medizinprodukte unterliegt in Deutschland vielfältiger Regulierung. In jüngerer Zeit wurde die Messlatte höhergelegt, was die Qualität der klinischen Evidenz hinsichtlich Wirksamkeit und Verträglichkei angeht. Zugleich wurden mit den neuen Paragraphen 137e und 137h des Sozialgesetzbuchs V neue Möglichkeiten für die Erprobung und befristete Kostenerstattung von Methoden eingeführt, die zwar Potential erkennen lassen, aber noch nicht die geforderte Evidenz vorweisen können.

Second EURORDIS Multi-Stakeholder Symposium on Improving Patient Access to Rare Disease Therapies
Brüssel / Belgien, 23. Februar 2017:

Michael Schlander:

Common Principles for Value Determination and Assessment.

Orphan drug regulation has been a great success in terms of stimulating research and development (R&D). With this success, pricing strategies of manufacturers of orphan medicinal products (OMPs) have become a reason of growing concern for policy makers and health care budget holders. High prices have traditionally been justified by the fixed cost caused by high out-of-pocket expenses, development times, and risk of failure associated with R&D into innovative medical technologies. In this environment, it is creating inconsistencies if and when manufacturers push for adaptive licensing and rapid market access – as this would necessarily imply not only undermining rigorous Health Technology Assessments, but simultaneously shifting risks and costs to other stakeholders, including patients.

2016

„5 Jahre Cluster Medizintechnologie – 5 Jahre Fraunhofer-Projektgruppe PAMB in Mannheim“
Offizielle Feierlichkeit,  Mannheim / Deutschland, 08. Dezember 2016:

Michael Schlander:

Neue Innovationsmodelle für die Gesundheitsversorgung der Zukunft.

(Eingeladene Eröffnungsrede)

Jahrestagung 2016 des Berufsverbands für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie in Deutschland, BKJPP, mit dem Leitthema „Sprache[n] in der Kinder- und Jugendpsychiatrie“
Regensburg / Deutschland, 03. November 2016:

Michael Schlander:

Sprache(n) der Gesundheitsökonomie.

(Eingeladener Plenumsvortrag)

International Society for Pharmacoeconomics & Outcomes Research (ISPOR)
19th Annual European Congress, Wien / Österreich, 29. Oktober – 02. November 2016:

Michael Schlander, Kathrin Stenner, Afschin Gandjour:

Drugs for Rare and Ultra-Rare Diseases in Europe: Analysis of Budget Impact and Cost Drivers.

(Poster-Präsentation, 01. November 2016)
Value in Health 19 (7), 2016: A598.

Michael Schlander, Harry Telser, Søren Holm, Deborah Marshall, Erik Nord, Jeff Richardson, Silvio Garattini, Peter Kolominsky-Rabas, Ulf Persson, Maarten Postma, Steven Simoens, Oriol de Solà-Morales, Keith Tolley, Mondher Toumi:

The European Social Preference Measurement (ESPM) Study: Conceptual Considerations and Implementation.

(Poster-Präsentation, 31. Oktober 2016)
Value in Health 19 (7), 2016: A508.

The preliminary study design discussed at ISPOR was based on a consensus achieved at a joint Scientific Steering Committee and International Advisory Board meeting in conjunction with the

Heidelberg Health Economics Summer School 2016,
Heidelberg / Deutschland: 26.-28. September 2016:

Workshop “SoPHI: ‘Social Preferences for Health Care Interventions’”: Pre-Test Questionnaire Design for the European Social Preferences (ESPM) Study Project, Phase I (28. September 2016)

11th European Conference on Health Economics (“Know the Ropes – Balancing Costs and Quality in Health Care”)
Hamburg / Deutschland, 13.-16. Juli 2016:

Paul M. Mitchell, Hareth Al-Janabi, Michael Schlander, Jeff Richardson, Angelo Iezzi, Joanna Coast:

Verstehen Sie? Validating the German translation of the ICECAP-A capability wellbeing measure in seven disease groups and a healthy population sample.

(Vortrag, 16. Juli 2016) Konferenzheft, S. 66.

Michael Schlander, Munir A. Khan, Angelo Iezzi, Aimee Maxwell, Oliver Schwarz, Jeff Richardson:

Multi-Attribute Utility (MAU) Instruments as Tools to Value Health-Related Quality of Life:
German Findings from the MIC Study.

(Vortrag, 16. Juli 2016) Konferenzheft, S. 71.

8th European Conference on Rare Diseases & Orphan Products (ECRD 2016)
Symposium zu “Game Changers in Research”, Edinburgh / Schottland, 26.-28. Mai 2016:

Michael Schlander, Søren Holm, Erik Nord, Jeff Richardson, Silvio Garattini, Peter Kolominsky-Rabas, Deborah Marshall, Ulf Persson, Maarten Postma, Steven Simoens, Oriol de Solà Morales, Keith Tolley, Mondher Toumi, Harry Telser:

The European Social Preferences Measurement (ESPM) study project: social cost value analysis, budget impact, commercial life cycle revenue management, and the economics of biopharmaceutical Research & Development (R&D).

(Eingeladener Vortrag, 28. Mai 2016)
Abstract publiziert im Orphanet Journal of Rare Diseases, 11, Suppl. 1 (2016): 143

2015

Health Economics Global Congress 2015 Europe
London / England, 06.-07. Dezember 2015:

Michael Schlander:

“The Burning Platform”:  Credibility of Corporate Health Economics.

(Eingeladener Vortrag, 07. Dezember 2015)

International Society for Pharmacoeconomics & Outcomes Research (ISPOR)
18th Annual European Congress, Mailand / Italien, 07.-11. November 2015:

Michael Schlander, Oliver Schwarz, Goetz-Erik Trott, Tobias Banaschewski:

Mental Health Disorder Prevalence Trends in Germany: A Longitudinal Study.

(Poster-Präsentation)
Value in Health 18 (7), 2015: A408.

2nd International Scientific and Practical Conference “Health Technology Assessment: Ways of Development in Russia”
Moskau / Russland, 02. November 2015:

Michael Schlander:

The Rationale for Multi-Criteria Decision Analysis (MCDA) as a Tool of HTA.

(Eingeladener Vortrag)

2015 HTAi International Conference
Oslo / Norwegen, 14.-17. Juni 2015:

Mireille Goetghebeur, Bjorn Hofmann, Alaa Hamed, Michael Schlander, Carole Longson, Payam Abrishami, Francois Meyer:

Communicating values and ethics across the healthcare decision-making continuum: where are we and what holistic multicriteria brings?

(Poster-Präsentation)

Michael Schlander, Søren Holm, Erik Nord, Jeff Richardson:

Improving the Usefulness of Health Economic Evaluations for Decision Makers: Social Value and the Case of Interventions for Rare and Ultra-Rare Disorders (URDs).

Workshop (moderiert von Deborah Marshall, Calgary) auf der HTAi International Conference in Oslo / Norwegen, 17. Juni 2015

ISPOR 20th Annual International Meeting
Philadelphia, PA / USA, 16.-20. Mai 2015:

Zeba M. Khan, Michael Schlander, Ron Akehurst, John Proach:

The Controversial Role of Cost-Effectiveness Analyses (CEA) and Incremental Cost-Effectiveness Ratio (ICER) Thresholds in Value-Based Assessments (VBA) of Health Technologies: What are the Future Challenges?

Eingeladener Vortrag bei einem Issue Panel auf dem ISPOR International Meeting, Philadelphia, PA / USA, 19. Mai 2015.

Michael Schlander, Silvio Garattini, Søren Holm, Peter Kolominsky-Rabas, Erik Nord, Ulf Persson, Maarten Postma, Jeff Richardson, Steven Simoens, Oriol Sola Morales, Keith Tolley, Mondher Toumi:

Interventions for Ultra-Rare Disorders (URDs) and the Logic of Cost Effectiveness.

Eingeladener Podiumsvortrag auf dem ISPOR International Meeting, Philadelphia, PA / USA, 18. Mai 2015.
Value in Health 18 (3), Mai 2015: A6.